India Glycols Limited has announced the rescheduling of crucial National Company Law Tribunal (NCLT) ordered meetings related to its Scheme of Arrangement. The meetings, originally scheduled for March 9, 2026, have been moved to March 24, 2026, following approval from the NCLT Allahabad Bench at Prayagraj.

Meeting Rescheduling Details

The company filed an interim application seeking rescheduling due to the unavailability of the Hon'ble Chairperson appointed by the NCLT to chair the meetings on March 9, 2026. The NCLT, through its revised order dated February 16, 2026, granted permission for the meetings to be convened on the new date.

Scheme of Arrangement Background

The meetings are being conducted for the purpose of considering and approving the Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The scheme involves three entities and their respective shareholders:

• India Glycols Limited (Applicant No. 1/Demerged Company)
• Ennature Biopharma Limited
• IGL Spirits Limited

Meeting Participants and Process

The NCLT has directed the convening of separate meetings for two distinct groups of stakeholders. Both meetings will be conducted through video conferencing to ensure broader participation and accessibility.

Regulatory Compliance and Documentation

The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the NCLT order available on its website for stakeholder reference. The communication was addressed to both BSE Limited (Scrip Code: 500201) and National Stock Exchange of India Limited (Symbol: INDIAGLYCO).

The company noted that a certified copy of the order is awaited, and the Scheme remains subject to applicable regulatory and other approvals. This rescheduling represents a procedural adjustment to accommodate the chairperson's availability while maintaining the integrity of the approval process for the proposed corporate restructuring.

India Glycols Limited has delivered a robust financial performance in Q3FY26, demonstrating strong growth momentum across its diversified business portfolio. The company's Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting held on February 10, 2026, as announced through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Strong Revenue and Profitability Growth

The company reported impressive financial metrics for Q3FY26, with significant improvements in both revenue and profitability compared to the previous year.

The company's EBITDA margin expanded significantly, reflecting improved operational efficiency and better cost management. Total expenses for the quarter stood at ₹2,462.67 crores compared to ₹2,371.13 crores in Q3FY25.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, India Glycols maintained its growth trajectory with consistent performance improvements.

Segment-wise Performance Analysis

India Glycols' diversified business model across four key segments contributed to the overall strong performance. The Potable Spirits segment remained the largest revenue contributor, while Bio-Fuel showed remarkable growth.

Q3FY26 Segment Revenue:

Segment Results (Profit Before Interest and Tax):

Corporate Developments and Strategic Initiatives

The company has undertaken several strategic initiatives during the period. The Board approved a demerger scheme involving the separation of Bio Pharma undertaking into Ennature Bio Pharma Limited and Spirits & Biofuel Undertaking into IGL Spirits Limited. The National Company Law Tribunal (NCLT) allowed the application on January 15, 2026, with the appointed date for the scheme being April 1, 2026.

Exceptional Items and Regulatory Impact

The company reported exceptional items of ₹0.83 crores during Q3FY26, related to additional employee benefit expenses arising from the implementation of New Labour Codes by the Government of India effective November 21, 2025. These codes consolidated multiple existing labour legislations into four unified frameworks.

Consolidated Performance

On a consolidated basis, India Glycols reported revenue from operations of ₹2,551.10 crores for Q3FY26, with net profit of ₹67.57 crores. The consolidated results include contributions from subsidiaries and joint venture Clariant IGL Specialty Chemicals Private Limited, which contributed ₹3.26 crores to the quarter's profit.

The company's strong performance across multiple segments, successful capital raising, and strategic restructuring initiatives position it well for continued growth in the coming periods.

Source: